Hepatology Communications: Now in pubmed central and applying for other indices
Gyongyi Szabo, Emma Brink – 2 February 2018
Toward personalized medicine for intrahepatic cholangiocarcinoma: Pharmacogenomic stratification of patients
Paula Olaizola, Maria J. Perugorria, Jesus M. Banales – 2 February 2018
Issue Information
2 February 2018
Elucidating the differences in pathogenicity between hepatitis E virus genotypes: The quest continues
Ann‐Sofie Vercouter, Philip Meuleman – 2 February 2018
People who survive an episode of severe alcoholic hepatitis should be advised to maintain total abstinence from alcohol
Stephen R. Atkinson, Andrew McQuillin, Marsha Y. Morgan, Mark R. Thursz – 2 February 2018
Reply
Yu Sun, Shu‐Yong Lin – 1 February 2018
Role of monocyte chemoattractant protein‐1 in liver fibrosis with transient myeloproliferative disorder in down syndrome
Kenichiro Kobayashi, Takako Yoshioka, Jun Miyauchi, Atsuko Nakazawa, Nobutaka Kiyokawa, Toshiro Maihara, Ikuya Usami – 1 February 2018 – Liver fibrosis is a common complication associated with transient myeloproliferative disorder (TMD) in Down syndrome (DS). The exact molecular pathogenesis that regulates disease progression is largely unknown. We recently found serum and/or urinary monocyte chemoattractant protein‐1 (MCP‐1) as a novel biomarker of liver fibrosis.
Reply
Qiang Liu, Laura Buccini, Daniele Pezzati, Ahmed Hassan, Teresa Diago Uso, Charles Miller, Cristiano Quintini – 1 February 2018
Correction
31 January 2018
Clinical studies investigating the effect of vitamin E therapy in patients with NASH
- Read more about Clinical studies investigating the effect of vitamin E therapy in patients with NASH
Sebastian Larion, Sandeep Khurana – 31 January 2018